The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the small-cap stocks with potential to rise 1000 percent. The company’s 2026 setup now rests on whether it can turn its off-the-shelf CAR T platform into clinical evidence across both cancer and autoimmune disease. In its May 13 first-quarter update, Allogene said its pivotal Phase 2 ALPHA3 trial of cema-cel in first-line consolidation treatment for large B-cell lymphoma had completed an interim futility analysis and would continue without modification. The trial is designed to evaluate whether treating patients who remain at high risk of relapse after initial therapy can improve event-free survival versus observation. The company also has a separate catalyst approaching in autoimmune disease. Allogene said initial data from the first dosing cohort of the Phase 1 RESOLUTION trial of ALLO-329 are expected in June 2026, including disease-related biomarkers, CAR T expansion, immune reconstitution, and early clinical outcomes. ALLO-329 is being studied across multiple autoimmune indications, including lupus, scleroderma, and inflammatory myositis. Allogene ended the first quarter with $266.9 million in cash, cash equivalents, and investments, and said its April public offering extended its cash runway into the first quarter of 2029.

Photo by National Cancer Institute on Unsplash Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a clinical-stage biotechnology company developing allogeneic CAR T cell therapies for cancer and autoimmune diseases. While we acknowledge the potential of ALLO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.  Disclosure: None. Follow Insider Monkey on Google News.